AXSM vs. CLS
AXSM (Axsome Therapeutics, Inc.) and CLS (Celestica Inc.) are both stocks. AXSM operates in Biotechnology (Healthcare), while CLS operates in Electronic Components (Technology). Over the past 10 years, AXSM returned 39.88%/yr vs 43.16%/yr for CLS. At a 0.17 correlation, their price movements are largely independent.
Performance
AXSM vs. CLS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, AXSM achieves a 28.75% return, which is significantly lower than CLS's 30.75% return. Over the past 10 years, AXSM has underperformed CLS with an annualized return of 39.88%, while CLS has yielded a comparatively higher 43.16% annualized return.
AXSM
- 1D
- 1.21%
- 1M
- 8.17%
- YTD
- 28.75%
- 6M
- 59.35%
- 1Y
- 110.12%
- 3Y*
- 47.19%
- 5Y*
- 29.93%
- 10Y*
- 39.88%
CLS
- 1D
- 3.98%
- 1M
- 2.92%
- YTD
- 30.75%
- 6M
- 13.42%
- 1Y
- 220.14%
- 3Y*
- 209.55%
- 5Y*
- 114.81%
- 10Y*
- 43.16%
AXSM vs. CLS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
AXSM Axsome Therapeutics, Inc. | 28.75% | 115.86% | 6.31% | 3.19% | 104.16% | -53.63% | -21.18% | 3,565.25% | -49.64% | -17.04% |
CLS Celestica Inc. | 30.75% | 220.27% | 215.23% | 159.80% | 1.26% | 37.92% | -2.42% | -5.70% | -16.32% | -11.56% |
Correlation
The correlation between AXSM and CLS is 0.18, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.18 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.16 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.19 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.18 |
Correlation (All Time) Calculated using the full available price history since Nov 20, 2015 | 0.17 |
Fundamentals
AXSM:
$12.04B
CLS:
$44.72B
AXSM:
-$3.74
CLS:
$8.28
AXSM:
16.71
CLS:
3.24
AXSM:
220.54
CLS:
21.31
AXSM:
$708.24M
CLS:
$13.81B
AXSM:
$655.82M
CLS:
$1.60B
AXSM:
-$172.72M
CLS:
$1.32B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
AXSM vs. CLS — Risk / Return Rank
AXSM
CLS
AXSM vs. CLS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Axsome Therapeutics, Inc. (AXSM) and Celestica Inc. (CLS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| AXSM | CLS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.41 | ||
| Sortino ratioReturn per unit of downside risk | +1.07 | ||
| Omega ratioGain probability vs. loss probability | 1.47 | 1.39 | +0.08 |
| Calmar ratioReturn relative to maximum drawdown | 5.99 | 7.58 | -1.59 |
| Martin ratioReturn relative to average drawdown | 17.16 | 18.88 | -1.72 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| AXSM | CLS | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.65 | 3.06 | -0.41 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.43 | 2.01 | -1.58 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.44 | 0.87 | -0.43 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.40 | 0.27 | +0.13 |
Drawdowns
AXSM vs. CLS - Drawdown Comparison
The maximum AXSM drawdown since its inception was -86.65%, smaller than the maximum CLS drawdown of -96.93%. Use the drawdown chart below to compare losses from any high point for AXSM and CLS.
Loading charts...
Drawdown Indicators
| AXSM | CLS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -86.65% | -96.93% | +10.28% |
Max Drawdown (1Y)Largest decline over 1 year | -18.50% | -29.24% | +10.74% |
Max Drawdown (3Y)Largest decline over 3 years | -36.45% | -53.96% | +17.51% |
Max Drawdown (5Y)Largest decline over 5 years | -72.91% | -53.96% | -18.95% |
Max Drawdown (10Y)Largest decline over 10 years | -81.26% | -80.60% | -0.66% |
Current DrawdownCurrent decline from peak | -0.35% | -18.18% | +17.83% |
Average DrawdownAverage peak-to-trough decline | -39.55% | -73.36% | +33.81% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.56% | 11.72% | -5.16% |
Volatility
AXSM vs. CLS - Volatility Comparison
The current volatility for Axsome Therapeutics, Inc. (AXSM) is 9.83%, while Celestica Inc. (CLS) has a volatility of 26.60%. This indicates that AXSM experiences smaller price fluctuations and is considered to be less risky than CLS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| AXSM | CLS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.83% | 26.60% | -16.77% |
Volatility (6M)Calculated over the trailing 6-month period | 32.98% | 55.08% | -22.10% |
Volatility (1Y)Calculated over the trailing 1-year period | 41.79% | 72.52% | -30.73% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 70.31% | 57.62% | +12.69% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 90.68% | 49.93% | +40.75% |
Dividends
AXSM vs. CLS - Dividend Comparison
Neither AXSM nor CLS has paid dividends to shareholders.
Financials
AXSM vs. CLS - Financials Comparison
This section allows you to compare key financial metrics between Axsome Therapeutics, Inc. and Celestica Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
AXSM vs. CLS - Profitability Comparison
AXSM - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Axsome Therapeutics, Inc. reported a gross profit of 176.48M and revenue of 191.20M. Therefore, the gross margin over that period was 92.3%.
CLS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported a gross profit of 437.20M and revenue of 4.05B. Therefore, the gross margin over that period was 10.8%.
AXSM - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Axsome Therapeutics, Inc. reported an operating income of -63.36M and revenue of 191.20M, resulting in an operating margin of -33.1%.
CLS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported an operating income of 272.10M and revenue of 4.05B, resulting in an operating margin of 6.7%.
AXSM - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Axsome Therapeutics, Inc. reported a net income of -64.54M and revenue of 191.20M, resulting in a net margin of -33.8%.
CLS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported a net income of 212.30M and revenue of 4.05B, resulting in a net margin of 5.3%.
Frequently Asked Questions
AXSM and CLS have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CLS has higher volatility (26.60%) compared to AXSM (9.83%). In terms of maximum drawdown, AXSM dropped -86.65% vs CLS's -96.93%.
CLS currently has the higher Sharpe Ratio (3.06 vs 2.65), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for AXSM and CLS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer